Bortezomib

CAS: 179324-69-7

Ref. TR-B675700

Produktinformation

• Name: Bortezomib
• Synonyme: Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-, Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- (9CI), Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-, DPBA, LDP 341, MG 341, MLN 341, NSC 681239, PS 314, PS 341, PS 341 (pharmaceutical), Radiciol
• Marke: TRC

Beschreibung

Stability Hygroscopic and Moisture Sensitive
Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);

Chemische Eigenschaften

• Molekulargewicht: 384.24
• Formel: C₁₉H₂₅BN₄O₄
• Farbe/Form: Neat
• InChl: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
• InChI Key: InChIKey=GXJABQQUPOEUTA-MYJWUSKBSA-N
• SMILES: CC(C)CC(NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O